Debt-to-Equity Ratio

Eli Lilly’s current Debt-to-Equity Ratio of 1.39x means the company uses $1.39 of debt for every $1 of shareholder equity, indicating a moderate reliance on borrowed funds to finance its operations.

This ratio sits well above the sector median of 0.73x, placing Lilly in the 76th percentile among its peers—meaning it is more leveraged than three-quarters of comparable companies. The metric does not show any trend because year-over-year and quarter-over-quarter changes are both marked as N/A, so there is no basis to assess whether leverage is increasing or decreasing. Without a trend, the elevated level alone signals higher financial risk compared to the sector norm, but it does not point to a clear near-term shift in that risk. This higher leverage could amplify both returns and losses, which aligns with a NEUTRAL overall verdict—the debt level is notable but not alarming on its own, and the absence of trend data prevents a stronger bullish or bearish stance.

Frequently Asked Questions

Closest Sector Peers